Skip to main content

Table 1 Baseline patient characteristics (n = 814)

From: Resolution of anaemia in a cohort of HIV-infected patients with a high prevalence and incidence of tuberculosis receiving antiretroviral therapy in South Africa

 

WHO anaemia severity classification at ART initiation

All (n = 814)

None (29.5%; n = 240)

Mild (28.0%; n = 228)

Moderate(38.1%; n = 310)

Severe (4.4%; n = 36)

P-value

Age (at baseline), median (IQR)

33 (29–39)

34 (29–40)

33 (29–40)

32 (28–37)

31 (27–37)

0.008

Gender

      

Male

224 (27.5)

102 (42.5)

87 (38.2)

30 (9.7)

5 (13.9)

<0.001

Female

590 (72.5)

138 (57.5)

141 (61.8)

280 (90.3)

31 (86.1)

 

WHO disease stage (at baseline)

      

1 or 2

185 (22.7)

56 (23.3)

55 (24.1)

69 (22.3)

5 (13.9)

0.584

3 or 4

629 (77.3)

184 (76.7)

173 (75.9)

241 (77.7)

31 (86.1)

 

Previous history of TB treatment

      

No

422 (51.8)

109 (45.4)

126 (55.3)

162 (52.3)

15 (69.4)

0.023

Yes

392 (48.2)

131 (54.6)

102 (44.7)

148 (47.7)

11 (30.6)

 

ART regimen

     

AZT-free throughout

646 (79.4)

207 (86.3)

187 (82.0)

221 (71.3)

31 (86.1)

<0.001

Any AZT exposure

168 (20.6)

33 (13.8)

41 (18.0)

89 (28.7)

5 (13.9)

 

CD4 cell count (cells/μL)a a

      

Median, IQR

104 (50–156)

113 (56–164)

117 (63–169)

93 (44–146)

85 (31–125)

0.002

<100

383 (47.2)

109 (45.6)

90 (39.7)

164 (53.1)

20 (55.6)

0.013

≥100

428 (52.8)

130 (54.4)

137 (60.4)

145 (46.9)

16 (44.4)

 

HIV viral load (log copies/mL), median (IQR) b

4.8 (4.4-5.2)

4.8 (4.3-5.1)

4.8 (4.4-5.2)

4.9 (4.5-5.3)

5.0 (4.7-5.3)

0.002

MCV (fL) c

      

Median, IQR

90 (86–95)

92 (88–96)

90 (87–94)

89 (84–94)

83 (75–95)

<0.001

<80

56 (7.0)

5 (2.1)

9 (4.0)

28 (9.2)

14 (38.9)

<0.001

80-100

671 (83.7)

205 (87.0)

200 (88.5)

250 (82.2)

16 (44.4)

 

>100

75 (9.4)

26 (11.0)

17 (7.5)

26 (8.6)

6 (16.7)

 

TB disease status

      

TB free in first year of ART

566 (69.5)

180 (75.0)

160 (70.2)

204 (65.8)

22 (61.1)

0.148

Referred TB

131 (16.1)

34 (14.2)

38 (16.7)

54 (17.4)

5 (13.9)

 

TB in first year of ART

117 (14.4)

26 (10.8)

30 (13.2)

52 (16.8)

9 (25.0)

 
  1. a3 missing CD4 cell count results, b5 missing HIV viral load results, c12 missing MCV results.
  2. Abbreviations: ART; antiretroviral therapy; AZT; zidovudine; IQR, interquartile range; MCV, mean corpuscular volume; TB, tuberculosis; WHO, World Health Organization. All values are proportions (%) unless otherwise stated.